» Articles » PMID: 24966464

Chemokines in Cancer Development and Progression and Their Potential As Targeting Molecules for Cancer Treatment

Overview
Publisher Wiley
Specialties Biochemistry
Pathology
Date 2014 Jun 27
PMID 24966464
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokines were initially identified as bioactive substances, which control the trafficking of inflammatory cells including granulocytes and monocytes/macrophages. Moreover, chemokines have profound impacts on other types of cells associated with inflammatory responses, such as endothelial cells and fibroblasts. These observations would implicate chemokines as master regulators in various inflammatory responses. Subsequent studies have further revealed that chemokines can regulate the movement of a wide variety of immune cells including lymphocytes, natural killer cells, and dendritic cells in both physiological and pathological conditions. These features endow chemokines with crucial roles in immune responses. Furthermore, increasing evidence points to the vital effects of several chemokines on the proliferative and invasive properties of cancer cells. It is widely acknowledged that cancer develops and progresses to invade and metastasize in continuous interaction with noncancerous cells present in cancer tissues, such as macrophages, lymphocytes, fibroblasts, and endothelial cells. The capacity of chemokines to regulate both cancerous and noncancerous cells highlights their crucial roles in cancer development and progression. Here, we will discuss the roles of chemokines in carcinogenesis and the possibility of chemokine targeting therapy for the treatment of cancer.

Citing Articles

Inflammation in cancer: therapeutic opportunities from new insights.

Xie Y, Liu F, Wu Y, Zhu Y, Jiang Y, Wu Q Mol Cancer. 2025; 24(1):51.

PMID: 39994787 PMC: 11849313. DOI: 10.1186/s12943-025-02243-8.


Level and clinical significance of serum CXC chemokine ligand 13 in patients with hepatocellular carcinoma.

Wu Y, Ran X, Li Q, Wu Y, Shen X, Mu M Transl Cancer Res. 2025; 14(1):424-433.

PMID: 39974413 PMC: 11833404. DOI: 10.21037/tcr-24-1306.


The Therapeutic Potential of Physical Exercise in Cancer: The Role of Chemokines.

Buzaglo G, Telles G, Araujo R, Junior G, Ruberti O, Ferreira M Int J Mol Sci. 2025; 25(24.

PMID: 39769501 PMC: 11678861. DOI: 10.3390/ijms252413740.


E3 ubiquitin ligase HECW2: a promising target for tumour therapy.

Shen H, Kou Q, Shao L, Zhang J, Li F Cancer Cell Int. 2024; 24(1):374.

PMID: 39529070 PMC: 11556196. DOI: 10.1186/s12935-024-03563-3.


SIRT5 participates in the suppressive tumor immune microenvironment of EGFR-mutant LUAD by regulating the succinylation of ACAT1.

Shouhan W, Qingchang L, Xiaodan S Heliyon. 2024; 10(21):e39743.

PMID: 39524872 PMC: 11543872. DOI: 10.1016/j.heliyon.2024.e39743.


References
1.
Waugh D, Wilson C . The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14(21):6735-41. DOI: 10.1158/1078-0432.CCR-07-4843. View

2.
Fernando R, Castillo M, Litzinger M, Hamilton D, Palena C . IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011; 71(15):5296-306. PMC: 3148346. DOI: 10.1158/0008-5472.CAN-11-0156. View

3.
Keeley E, Mehrad B, Strieter R . Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res. 2010; 317(5):685-90. PMC: 3073599. DOI: 10.1016/j.yexcr.2010.10.020. View

4.
Amersi F, Terando A, Goto Y, Scolyer R, Thompson J, Tran A . Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res. 2008; 14(3):638-45. PMC: 2760931. DOI: 10.1158/1078-0432.CCR-07-2025. View

5.
Steer H, Lake R, Nowak A, Robinson B . Harnessing the immune response to treat cancer. Oncogene. 2010; 29(48):6301-13. DOI: 10.1038/onc.2010.437. View